Drug trial shows hope for less invasive treatment of rare foetal blood disease
A new investigational drug, nipocalimab, has shown promising results in altering the standard treatment for Hemolytic Disease of the Fetus and Newborn (HDFN), potentially delaying or preventing anemia and reducing the need for intrauterine blood transfusions in high-risk pregnancies.
HDFN is a severe condition where the blood types of a mother and her foetus are incompatible, leading to life-threatening anemia in the baby.
Currently, treatment typically involves multiple ultrasound-guided intrauterine blood transfusions, which carry risks like fetal death, premature rupture of membranes, and pre-term birth.
“If further studies support using nipocalimab to treat HDFN, it will make treating the foetus in these pregnancies safer and easier for pregnant moms,” said Dr. Kenneth Moise Jr. a ...










